drugset / Trial / NCT03530293
Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.
Timeline
- Start
- 2018-04-17
- Primary completion
- 2019-07-16
- Completion
- 2019-07-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valbenazine | Small molecule | — | — |